期刊文献+

简便、快速自动化合成肿瘤显像剂^(18)F-氟代乙酸盐和1-H-1-(3-^(18)F-2-羟基丙基)-2-^(18)F-硝基咪唑 被引量:5

Simple and rapid synthesis of tumor imaging agents^(18)F-FAC and ^(18)F- FMISO
下载PDF
导出
摘要 用“一锅法”和TRACERlab FXF-N自动化合成仪系统合成了18F-氟代乙酸盐(18F-FAC)和1-H-1-(3-18F-2-羟基丙基)-2-硝基咪唑(18F-FMISO)。以溴代乙酸苄酯为前体,在同一反应瓶中经亲核氟化、NaOH水解两步反应及Sep Pak小柱分离纯化制备了18F-FAC注射液,总合成时间小于40min,未经校正的放化产率和放化纯度分别大于45%和99%。以1-(2’-硝基-1’-咪唑基)-2-O-四氢吡喃基-3-O-甲苯磺酰基丙二醇为原料,用类似方法制备了18F-FMISO注射液,总合成时间小于40 min,未经校正的放化产率和放化纯度分别大于40%和95%。采用“一锅法”自动化合成18F-FAC和18F-FMISO注射液,操作简便,该工艺可用制备2-18F-2-脱氧-D-葡萄糖(18F-FDG)的全自动化合成模块来制备18F-FAC和18F-FMISO注射液。 The fully automated synthesis of tumor imaging agents ^18F-fluoroacetate (^18F-FAC) and 1-H-1-(3-[^18F]fluoro-2-hydro-xylpropyl)-2-nitroimidazole (^18F-FMISO) via "one-pot" procedure in TRACERlab FXF-N synthesizer is described. ^18F-FAC injection was prepared via two-step reactions including nucleophilic fluorination of the precursor benzyl bromoacetate with ^18F-fluoride and subsequently hydrolysis with NaOH at the same reaction vessel, and purified with Sep Pak cartridges. The uncorrected radiochemical yield of ^18F-FAC was about 45%, the radiochemical purity was more than 99%, and the whole synthesis time was less than 40 min. ^18F-FMISO injection was prepared by the similar method. The uncorrected radiochemical yield of ^18F-FMISO is above 40%, the radiochemical purity is above 95%, and the total synthesis time was less than 40 min. The fully automated one-pot synthesis procedures of ^18F-FAC and ^18F-FMISO injection are easy to operate and can be performed in any automated system designed for the synthesis of 2-^18F-2-deoxy-D-glucose (^18F-FDG) by the nucleophilic substitution.
出处 《核技术》 EI CAS CSCD 北大核心 2006年第8期581-586,共6页 Nuclear Techniques
基金 广东省科技计划资助项目(2003C34304)
关键词 ^18F-氟代乙酸盐 ^18F-FMISO 肿瘤显像剂 乏氧显像剂 自动化合成 ^18F-Fluoroacetate, ^18F-FMISO, Tumor imaging agent, Hypoxia imaging agent, Fully automated synthesis
  • 相关文献

参考文献12

  • 1唐刚华,唐小兰,王明芳,郭晓君.高产率自动化合成2-^(18)F-2-脱氧-D-葡萄糖[J].核技术,2006,29(7):531-536. 被引量:11
  • 2Matthies A, Ezziddin S, Ulrich E M, et al. Eur J Nucl Med Mol Imaging, 2004, 31(5): 797
  • 3Padgett H C, Schmidt D G, Luxen A, et al. Appl RadiatIsot, 1989, 40(5): 433-445
  • 4Sykes T R, Ruth T J, Adam M J. Nucl Med Biol, 1986,13(5): 497-500
  • 5Jeong J M, Lee D S, Chung J K, et al. J Labeled Compd Radiopharm, 1997, 36(5): 395-399
  • 6唐刚华,黄祖汉.PET药物及其研究现状与进展[J].国外医学(放射医学核医学分册),1999,23(5):193-197. 被引量:19
  • 7Graham M M, Peterson L M, Link J M, et al. J Nucl Med,1997, 38(10): 1631-1636
  • 8Patt M, Kuntzsch M, Machulla H J. J Radioanal Nucl Chem, 1999, 2411(3): 925-927
  • 9Kamaminen E L, Kyllonen T, Nihtila O, et al. J Label Compd Radiopharm, 2004, 47(1): 37-45
  • 10Jerabek P A, Patrick T B, Kilbourn R, et al. Appl Radiat Isot, 1986, 37(7): 599-605

二级参考文献14

  • 1Gronroos T, Bentzenl L, Marjamki M, et al. Comparison of the Biodistribution of Two Hypoxia Markers [^18F] FETNIM and [^18F] FMISO in an Experimental Mammary Carcinoma [ J ]. Eur J Nucl Med Mol Imaging, 2004, 31(4):513~520.
  • 2Patt M, Kuntzsch M, Machulla H J. Preparation of Fluoromisonidazole by Nucleophilic Substitution on THP-protected Precursor: Yield Dependence on Reaction Parameters[ J ]. J Radioanalyt Nucl Chem,1999, 240(3):925~927.
  • 3Kamarainen E L, Kyllonen T, Nihtila O, et al.Preparation of Fluorine-18-labelled Fluoromisonidazole Using Two Different Synthesis Methods [ J ]. J Label Compd Radiopharm, 2004, 47(1):37~45.
  • 4Jerabek P A, Patrick T B, Kilbourn R, et al. Synthesis and Biodistribution of ^18F-labeled Fluoromisonidazoles: Potential in vivo Markers of Hypoxia Tissue[ J ]. Appl Radiat Isot, 1986, 37(7):599~605.
  • 5Graham M M, Peterson L M, Link J M, et al. Fluorine-18-fluoromisonidazole Radiation Dosimetry in Imaging Studies[ J ]. J Nucl med, 1997, 38 (10)1631~1636.
  • 6Lemaire C,Damhaut P H,Lauricella B,et al.J Label Compd Radiopharm,2002,45(4):435-447
  • 7Fuchtner F,Steinbach J,Mading P,et al.Appl Radiat Isot,1996,47(1):61-66
  • 8Hamacher K,Coenen H H,Stocklin G.J Nucl Med,1986,27(1):235-238
  • 9Chaly T,Dahl J R.Nucl Med Biol,1989,16(4):385-387
  • 10Fowler J S,Ido T.Sem Nucl Med,2002,32(1):6-12

共引文献32

同被引文献63

  • 1陈立光,唐安戊.^(11)C-标记PET显像剂的合成及应用[J].现代临床医学生物工程学杂志,2005,11(1):10-14. 被引量:1
  • 2唐刚华,唐小兰,王明芳,罗磊,甘满权.肿瘤显像剂^(18)F-氟代乙酸盐的自动化合成[J].核技术,2006,29(1):59-62. 被引量:9
  • 3Ho CL,Yu SCH,Yeung DWC.11C-acetate PET imaging in hepatocellular carcinoma and other liver masses.J Nucl Med,2003,44:213-221.
  • 4Lodi F,Trespidi S,Di Pierro D,et al.A simple tracerlab module modification for automated on-column 11C-roethylalian and 11C-carboxylation.Appl Radiat Isot,2007,65:691-695.
  • 5Ponde DE,Dence CS,Oyama N,et al.^18F-fluoroacetate:a potential acetate analog for prostate tumor imaging --in vivo evaluation of ^18F-fluoroacetate versus 11C-acetate.J Nucl Med,2007,48:420-428.
  • 6Sun LQ,Mort T,Dence CS,et al.New approach to fully automated synthesis of sodium ^18F-fluoracetate --a simple and fast method using a commercial synthesizer.Nucl Med Biol,2006,33:153-158.
  • 7Berfidge MS,Cassidy EH,Miraldi F,et al.11C-acetate and 11C-methionine:improved syntheses and quality control.Appl Radiat Isot,1995,46:173-175.
  • 8Visvikis D, Francis D, Mulligan R. Comparison of Methodologies for the in vivo Assessment of JSFLT Utilization in Colorectal Cancer. Eur J Nucl Med Mol Imaging, 2004, 31 : 169 - 178.
  • 9Oyama N, Akino H, Suzuki H, et al. FDG PET for evaluating the change of glucose metabolism in prostate cancer after androgen ablation. Nucl Med Commun, 2001, 22 (9): 963 - 969.
  • 10Choi Y, Huang SC, Hawkins RA, et al. A refined method for quantification of myocardial oxygen consumption rate using mean transit time with carbon - 11 - acetate and dynamic PET. J Nucl Med, 1993, 34 ( 11 ) : 2038 - 2043.

引证文献5

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部